http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
계기성,최우식,이선아 조선대학교 구강생물학연구소 2002 Oral Biology Research (Oral Biol Res) Vol.26 No.2
In cases of anterior crossbite patients, there are many problems. They are dissatisfied with facial appearance and in difficulties for speaking, and sometimes are related to reduced vertical dimension. Vertical dimension is defined distances between two points which one is on maxilla and the other is on mandible. Loss of vertical dimension may causes temporomandibular disorder, loss of masticatory function, and collapse of occlusion. This is a clinical study of 50 years old male with reduced vertical dimension and anterior-crossbite. We treated patient with fixed bridge and conventional removable partial denture, and then the activity of masseter and temporalis muscle were recorded and analyzed by means of Biopak?? system(Bioresearch Inc., Millwakee Wisconsin). The result was satisfactory functionally and esthetically.
Hepatitis B Reactivation among Chronic Hepatitis C Patients Treated with Direct Acting Antivirals
( Hee Yeon Kim ),( Chang Wook Kim ),( Jin Ah Kim ),( Mi Ju Cheon ),( Chan Ran You ),( Sang Wook Choi ),( Se Hyun Cho ),( Joon-Yeol Han ),( Do Seon Song ),( U Im Chang ),( Jin Mo Yang ),( Sung Won Lee 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: This study aimed to investigate hepatitis B virus (HBV) reactivation among hepatitis C virus (HCV) infected patients treated with oral direct acting antiviral (DAA) therapy in areas endemic for HBV in Korea. Methods: A total of 821 HCV-infected patients receiving oral DAA therapy from March 2015 to November 2016 were evaluated. Serum HBV DNA and HCV RNA was regularly assessed during and after DAA treatment in patients with HBV-HCV coinfection. HBV virological reactivation was defined as a >1 log increase in HBV DNA from baseline or a reappearance of HBV DNA for those with baseline undetectable HBV DNA. Clinical reactivation was defined as a serum alanine aminotransferase level ≥3-fold over the upper limit of normal or > 100 U/L. Results: Prior to DAA therapy 95.8% (787/821) had HBsAg testing and 1.7% (13/787) were positive. HBV virological reactivation was found in 7 (53.8%) of the 13 patients. HBV-related clinical reactivation was not observed in our cohort. Conclusions: For HBV-HCV co-infected patients, the risk of HBV virological reactivation was present after oral DAA treatment for HCV infection. Monitoring the HBV DNA level during oral DAA therapy for HCV infection is warranted.